Shuttle Pharmaceuticals Holdings (Shuttle Pharmaceuticals Holdings) Retained Earnings : $-17.22 Mil (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Shuttle Pharmaceuticals Holdings Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Shuttle Pharmaceuticals Holdings's retained earnings for the quarter that ended in Mar. 2024 was $-17.22 Mil.

Shuttle Pharmaceuticals Holdings's quarterly retained earnings declined from Sep. 2023 ($-13.85 Mil) to Dec. 2023 ($-15.49 Mil) and declined from Dec. 2023 ($-15.49 Mil) to Mar. 2024 ($-17.22 Mil).

Shuttle Pharmaceuticals Holdings's annual retained earnings declined from Dec. 2021 ($-5.80 Mil) to Dec. 2022 ($-8.90 Mil) and declined from Dec. 2022 ($-8.90 Mil) to Dec. 2023 ($-15.49 Mil).

Shuttle Pharmaceuticals Holdings Retained Earnings Historical Data

The historical data trend for Shuttle Pharmaceuticals Holdings's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shuttle Pharmaceuticals Holdings Retained Earnings Chart

Shuttle Pharmaceuticals Holdings Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Retained Earnings

-4.54

-5.80

-8.90

-15.49

Shuttle Pharmaceuticals Holdings Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Retained Earnings	Get a 7-Day Free Trial									-9.87	-12.05	-13.85	-15.49	-17.22

Shuttle Pharmaceuticals Holdings Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Shuttle Pharmaceuticals Holdings (NAS:SHPH) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Shuttle Pharmaceuticals Holdings (Shuttle Pharmaceuticals Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shuttle Pharmaceuticals Holdings Inc (NAS:SHPH) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

N/A

Address

One Research Court, Suite 450, Rockville, MD, USA, 20850

Website

https://www.shuttlepharma.com

Shuttle Pharmaceuticals Holdings Inc is a clinical stage pharmaceutical company leveraging our proprietary technology to develop novel therapies designed to cure cancers. The company's goal is to extend the benefits of cancer treatments by leveraging insights into the pillars of cancer therapy: surgery, radiation therapy, chemotherapy, and immunotherapy.

Executives

Milton Brown	director	SHUTTLE PHARMACEUTICALS HOLDINGS, INC., ONE RESEARCH COURT, SUITE 450, ROCKVILLE MD 20850
Bette Jacobs	director	SHUTTLE PHARMACEUTICALS HOLDINGS, INC., 1 RESEARCH COURT, SUITE 450, ROCKVILLE MD 20850
Peter Dritschilo	officer: President and COO	SHUTTLE PHARMACEUTICALS HOLDINGS, INC., SUITE 450, ROCKVILLE MD 20850
Anatoly Dritschilo	director, 10 percent owner, officer: CEO and Chairman	SHUTTLE PHARMACEUTICALS HOLDINGS, INC., ONE RESEARCH COURT, SUITE 450, ROCKVILLE MD 20850
Tyvin Rich	officer: Chief Medical Officer	SHUTTLE PHARMACEUTICALS HOLDINGS, INC., ONE RESEARCH COURT, SUITE 450, ROCKVILLE MD 20850
Mira Jung	officer: Chief Scientific Officer	SHUTTLE PHARMACEUTICALS HOLDINGS, INC., ONE RESEARCH COURT, SUITE 450, ROCKVILLE MD 20850
Hoek Michael Vander	officer: Chief Financial Officer	SHUTTLE PHARMACEUTICALS HOLDINGS, INC., SUITE 450, ROCKVILLE MD 20850
Steven M Richards	director	SHUTTLE PHARMACEUTICALS HOLDINGS, INC., ONE RESEARCH COURT, SUITE 450, ROCKVILLE MD 20850
William Adkins	director	SHUTTLE PHARMACEUTICALS HOLDINGS, INC., ONE RESEARCH COURT, SUITE 450, ROCKVILLE MD 20850
Joshua Schafer	director	SHUTTLE PHARMACEUTICALS HOLDINGS, INC., ONE RESEARCH COURT, SUITE 450, ROCKVILLE MD 20850
Chris Senanayake	director	SHUTTLE PHARMACEUTICALS HOLDINGS, INC., ONE RESEARCH COURT, SUITE 450, ROCKVILLE MD 20850